Rhumbline Advisers Buys 17,316 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

Rhumbline Advisers lifted its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 16.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,840 shares of the company’s stock after purchasing an additional 17,316 shares during the quarter. Rhumbline Advisers owned 0.08% of Wave Life Sciences worth $1,544,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. James J. Burns & Company LLC lifted its position in shares of Wave Life Sciences by 11.0% in the fourth quarter. James J. Burns & Company LLC now owns 111,111 shares of the company’s stock worth $1,374,000 after purchasing an additional 11,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Wave Life Sciences by 126.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 54,267 shares of the company’s stock worth $671,000 after buying an additional 30,276 shares during the last quarter. Moody Aldrich Partners LLC increased its holdings in Wave Life Sciences by 31.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company’s stock worth $4,929,000 after buying an additional 95,413 shares during the last quarter. KBC Group NV acquired a new position in Wave Life Sciences during the fourth quarter worth $67,000. Finally, SG Americas Securities LLC increased its holdings in Wave Life Sciences by 46.1% during the fourth quarter. SG Americas Securities LLC now owns 53,419 shares of the company’s stock worth $661,000 after buying an additional 16,856 shares during the last quarter. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Stock Performance

WVE stock opened at $11.23 on Wednesday. The company’s 50-day simple moving average is $11.63 and its 200 day simple moving average is $11.19. Wave Life Sciences Ltd. has a 52 week low of $4.25 and a 52 week high of $16.74. The company has a market capitalization of $1.71 billion, a PE ratio of -10.12 and a beta of -1.09.

Analyst Ratings Changes

WVE has been the topic of a number of recent analyst reports. Truist Financial boosted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, November 13th. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Mizuho upped their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.